Follicular Lymphoma

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

“It's an exciting time with all the novel agent development in relapsed indolent lymphoma,” according to Brad S. Kahl, MD.

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

The investigational agent glofitamab produced high responder rates in combination with obinutuzumab in multiple relapsed or refractory follicular lymphoma.

Based on findings from extended follow-up analysis of the phase 2 ELARA study, tisagenlecleucel is a beneficial treatment for patients with relapsed or refractory follicular lymphoma.

Monsunetuzumab induced deep and durable remission in patients with heavily pretreated follicular lymphoma.

The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.

Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

The FDA has accepted a biologics license application for tisagenlecleucel and granted it priority review as a potential treatment for relapsed or refractory follicular lymphoma after 2 lines of therapy

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

Obinutuzumab is associated with greater toxicity compare to rituximab in follicular lymphoma.

An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.

Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.

The study is currently recruiting in Chicago, Illinois.

According to Eliza A. Hawkes, MD, the phase 2 1st FLOR trial showed the positive efficacy of frontline nivolumab in combination with rituximab.

Enrollment in the phase 2b PARADIGME trial of 177Lu lilotomab satetraxetan (Betalutin) in patients with follicular lymphoma has continued despite the surge of the COVID-19 Delta variant.

The first patient with marginal zone lymphoma has been dosed in the global phase 2 TIDAL study of zandelisib, a phosphatidylinositol 3-kinase (PI3K) delta inhibitor, for the treatment of MZL and follicular lymphoma in patients who have received at least 2 or more prior therapies.

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.

Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.

In the phase 2 ELARA trial, treatment with the autologous CD19-directed chimeric antigen receptor T-cell therapy, tisagenlecleucel, achieved a high response rate that appeared durable, in patients with relapsed/refractory follicular lymphoma.

Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.

Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.